Veru plans Phase 2 trial of oral sabizabulin in daraxonrasib-resistant metastatic pancreatic cancer

• Veru will advance oral sabizabulin into a planned Phase 2 trial for metastatic KRAS-driven pancreatic cancer resistant to daraxonrasib.
• The decision follows newly presented preclinical studies showing sabizabulin remained effective in models of daraxonrasib resistance.
• Veru plans to seek FDA feedback in a pre-IND meeting in Q4 2026 to shape the trial’s scope.
• The shift ends work on sabizabulin for chronic inflammation tied to atherosclerotic cardiovascular disease.
• Separately, Veru reaffirmed its enobosarm obesity program timeline, with an interim Phase 2b readout targeted for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080817PRIMZONEFULLFEED9822345) on September 08, 2026, and is solely responsible for the information contained therein.